Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials

Chia Siang Kow¹, Mamoon Aldeyab², Syed Shahzad Hasan^{2

3}

Affiliations

¹ School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
² School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
³ School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia.

Meta-Analysis

Chia Siang Kow et al. J Med Virol. 2021 Apr.

. 2021 Apr;93(4):1860-1861.

doi: 10.1002/jmv.26638. Epub 2020 Nov 10.

Chia Siang Kow¹, Mamoon Aldeyab², Syed Shahzad Hasan^{2

3}

¹ School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
² School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
³ School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia.

No abstract available

References

1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19-preliminary report. N Engl J Med. 2020.
1. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med. 2020.
1. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020:e2016349.
1. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578.
1. Jiang Y, Chen D, Cai D, Yi Y, Jiang S. Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: a network meta-analysis. J Med Virol. 2020. https://doi.org/10.1002/jmv.26443